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BACKGROUND: Mucopolysaccharidosis type II (Hunter's syndrome) is an X-linked chromosomal storage 
disorder due to deficiency of the lysosomal enzyme iduronate-2-sulfatase with patients rarely living till 
adulthood. Failure to identify patients early could contribute to an increased morbidity as identified in this 
case report.  
CASE DETAILS: An eight year old patient with Hunter's syndrome identified five years after disease onset 
with severe cardiovascular complications exemplifies the challenges faced in resource-limited countries 
towards making diagnosis and treatment of rare conditions. Elevated urinary glycosaminoglycans levels or a 
strong clinical suspicion of Hunter's syndrome, as identified in the index case, is a prerequisite for enzyme 
activity testing. Urinary mucopolysaccharide(MPS) level was 69.6mg/mmol(normal range is 0.0 - 
11.6mg/mmol), and the confirming MPS electrophoresis analysis showed elevated heparan sulphate in the 
urine sample. Enzyme activity testing, with absent or very low iduronate-2-sulfatase activity, is diagnostic. 
However, the scarce availability and high cost of these tests is another constraint in making a diagnosis. 
CONCLUSION: Identification and management of mucopolysaccharidosis type II pose a problem in 
resource-constrained countries due to late presentation, lack of facility for diagnosis and treatment, cost and 
expertise required for the management. 






Hunter's syndrome is a subset of 
Mucopolysaccharidosis, a group of metabolic 
disorders, caused by deficiency in the activity of 
lysosmal enzymes needed to breakdown long chain 
sugar molecules called glycosaminoglycans (1).
 
It is 
a rare X-linked recessive disorder characterized by 
deficiency of iduronate-2-sulfatase, which catalyses a 
step in the catabolism of glycosaminoglycans 
(GAGs) resulting in accumulation of heparan and 
dermatan sulfate in many organs and tissues (2). 
The syndrome occurs in all ethnic groups, but a higher 
incidence has been reported among the Jews in Israel 
(3). The incidence ranges from one case per 72,000 
male live births in Northern Ireland to one case per 
518,000 male live births in British Columbia (4-8). 
The incidence of the disease is not known in Nigeria 
although two cases have been reported. 
The disease is characterized by coarse facie, large and 
protruding tongue, infection and obstruction of the 
upper airways, hypoacusis, inguinal and umbilical 
hernia, joint contractures, skeletal abnormalities, 
hepatosplenomegaly, cardiac valve disease and and 
slowly progressive mental deterioration with 
behavioural alterations between the ages of 2 and 6 
years (4,9). Patients tend to be tall for their age until 4 
or 5 years of age, when they begin to lag behind 
unaffected boy. Hunter's syndrome is often described 
as having two phenotypes, attenuated and severe, on 
the basis of life expectancy and the presence or 
absence of central nervous system complications 
(4,10,11). Due to the insidious onset of the disease 
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with the presence of recurrent ear infections, 
identification may become possible only when the 
coarse features appear usually at the age of two to 
three years (9).  
We report a patient with Hunter's syndrome who 
was identified late with severe cardiovascular 
complications. Also, highlighted are the compounding 
challenges in the management of this condition in a 




An 8 year old boy admitted via respiratory clinic due 
to swollen legs and abdomen of 8 months duration and 
progressive difficulty n ibreathing of 4 months. His 
parents noticed an abnormal facial appearance when 
he was about 3 years old, described as prominent 
forehead, protruding eyes and enlarged jaws with 
thickened skin. He had presented at the Ear, Nose and 
Throat clinic with complaints of snoring and recurrent 
ear discharge with resultant hearing impairment. He 
was on regular follow-up at the ENT outpatient clinic 
for 5 years without identification of the background 
dysmorphic features, and was subsequently referred to 
the paediatric pulmonology clinic due to the 
progressive difficulty in breathing. There had been a 
regression in language development as he could no 
longer communicate in sentences, which he was 
previously able to do. No other significant past 
medical history was identified.  
He was exclusively breastfed for 6 months and 
then complementary feeds added to his diet. 
Breastfeeding was stopped at the age 14 months. 
The eldest of 2 children, his sibling was a 5 year 
old healthy boy, and there was no positive family 
history of a similar clinical condition. The patient 
started pre-nursery school at the age of 2 years, but 
had to be withdrawn 2 years later due to recurrent 
illnesses, requiring frequent hospital visits. He lived 
with his paternal grandmother following the 
separation of his parents when he was 4 years old. The 
father was an artisan and the mother a petty trader. 
Examination revealed a big head with frontal bossing 
and caput quadratum, low set ears, depressed nasal 
bridge, up-turned nose, enlarged jaws, protruding 
tongue, short neck and short stubby digits with 
papular lesions on the upper trunk (Figures 1 and 2). 
He had an inspiratory stridor, was centrally cyanosed, 
afebrile, not pale, anicteric and had pitting oedema up 
to the thigh and sacrum. His height was 98cm (81% of 
expected). He had joint stiffness with the fore-arms 








Figure 2: Slightly flexed forearms at elbow joints and 
gross abdominal distension with umbilical hernia 
 
He had tachycardia, hyperactive precordium and apex 
beat in the 5
th
 intercostals space 2cm lateral to 
midclavicular line. There was grade 3 pansystolic 
murmur loudest at the apex, radiating to the axilla. He 
was tachypneic and had transmitted sounds in the 
chest. The abdomen was distended with an umbilical 
hernia (Figure 2); there was tender 
hepatosplenomegaly and ascites demonstrable by fluid 
thrill.  
Full blood count revealed a WBC of 4.1x10
9
/L 
with 79% lymphocytes, 16% neutrophils and 
anisopoikilocytosis, macrocytosis, hypochromia and 
target cells on blood film. Haemoglobin genotype was 
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AA identified using cellulose acetate Hb 
electrophoresis. Serum electrolytes were essentially 
normal. Lateral skull X-ray showed a widened J-
shaped sella turcica (Figure 3). There was a reduction 
in the vertical height, posterior displacement and 
anterior beaking of L3 vertebra and reduction of L2-
L3 disc space (Figure 4). Echocardiography showed 
mitral valve prolapse with severe regurgitation, 




Figure3: Lateral skull X-ray showing a widened J-
shaped sella turcica 
Urinary creatinine was 1.25mmol/L, urate: creatinine 
ratio 1.46(0.13 - 0.94) and urinary 
mucopolysaccharide of 69.6mg/mmol (normal range 
0.0 - 11.6). The mucopolysaccharide (MPS) dimethyl 
methylene blue (DMB) screening was positive and the 
confirming MPS electrophoresis analysis showed 
elevated heparan sulphate in the urine sample. 
He was examined during admission by the 
cardiologist, neurologist, otorhinolaryngologist, 
ophthalmologist, dermatologist, orthopaedic surgeon 
and physiotherapist. The child was on diuretics, 
captopril and also sildenafil for the severe pulmonary 
hypertension. Abdominal paracentesis was done twice 
and serial echocardiograms was done to monitor the 
size of pericardial effusion and pulmonary pressure. 
Enzyme replacement therapy could not be commenced 
because of financial difficulties and non-availability in 
this environment. He was discharged after about 3 
weeks of admission following immense pressure by 
the parents while he was relatively stable. He was 
never returned for follow-up despite phone calls to the 
parents. He died at home a month after discharge from 





Figure 4: Anterior beaking of L3 vertebra (white 





Hunter's syndrome can be extremely difficult to 
diagnose before irreversible organ and tissue damage 
occurrs because of insidious onset and overlap in signs 
and symptoms with common childhood complaints  
(10). The challenges faced in resource poor countries 
in making diagnosis and treatment of rare conditions 
has been exemplified with the case reported. 
Our patient presented with typical features of Hunter's 
syndrome as highlighted in earlier case reports (1,2). 
Ogunbiyi et al (2) made the diagnosis mainly based on 
physical and radiological features, while in addition to 
these parameters, Chinawa et al (1) did a urine 
chemistry which showed normal urinary 
mucopolysaccharide levels. In contrast, the index 
patient was identified with a combination of physical 
and radiological features as well as urinary features of 
highly elevated urinary mucopolysaccharide with a 
positive mucopolysaccharide (MPS) dimethyl 
methylene blue (DMB) screen and the confirming 
MPS electrophoresis analysis which showed elevated 
heparan sulphate. The index patient and the patients in 
the earlier reports had similar physical and 
radiological features. Thus, an initial screening based 
on the physical appearance and radiological features 
will aid the diagnosis when Hunter's syndrome is 
suspected.   
In order to help optimize patient outcomes, early 
identification, diagnosis and referral are critical. 
Although not curative, early treatment with enzyme 
replacement therapy before irreversible organ damage 





occurs may result in the greatest clinical benefit  (10). 
The index patient was identified late already 
manifesting features of cardiac damage and other 
complications. The patient also presented late after 
being referred to a paediatrician due to financial 
constraints. Ignorance, poor health seeking behaviour 
and poverty are among the reasons for late 
presentation in developing countries. 
The level of urinary GAGs is increased in 
patients with any Mucopolysaccharidosis; so the 
detection of excessive urinary GAG excretion is 
generally the first diagnostic approach although 
patients with a family history of 
Mucopolysaccharidosis II should proceed directly to 
enzyme activity assays and/or molecular genetic 
analyses (11). When urinary GAG levels are elevated, 
or there is a strong clinical suspicion of Hunter's 
syndrome as was noted in the index case, enzyme 
activity testing should be conducted. Unavailability of 
facilities for proper investigation also contributed to 
the difficulty in the management of the index case as 
the urinary GAG had to be done abroad. Absent or 
very low iduronate-2-sulfatase activity is diagnostic 
(10); however, the cost of doing this test is very high 
in resource-constrained countries or where the facility 
is not even available.   
Management is multidisciplinary including 
cardiology, neurosurgery, ophthalmology, 
orthopaedics, otorhinolaryngology and pulmonology. 
Supportive services such as physiotherapy, speech 
therapy, audiology, dentistry and behavioural therapy 
are also involved (10). Patients and caregivers are 
often overwhelmed with the number of paediatric 
subspecialties that are involved in care as was the case 
in this instance. This could have contributed to the 
refusal for readmission.  
In conclusion, identification and management of 
mucopolysaccharidosis type II in affected patients 
pose a problem in resource-constrained countries due 
to late identification and presentation, lack of facilities 
for diagnosis and treatment, as well as the cost and the 
expertise required for the management. A high index 
of suspicion based on the clinical features is needed to 
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